Available Trials

Prostate Cancer

  • STAR 16238

    A Multicenter, Randomized, Open-Label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients with Metastatic Castration Resistant Prostate Cancer Associated with Homologous Recombination Deficiency

    Available at 8 locations

  • USOR 16237

    A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer Associated with Homologous Recombination Deficiency

    Available at 8 locations

  • USOR 17149

    A Phase 2 Study of Nivolumab in Combination with Either Rucaparib, Docetaxel, or Enzalutamide in Men with Castration-resistant Metastatic Prostate Cancer

    Available at 4 locations

  • USOR 16160

    A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED MULTICENTER TRIAL TESTING IPATASERTIB PLUS ABIRATERONE PLUS PREDNISONE/PREDNISOLONE, RELATIVE TO PLACEBO PLUS ABIRATERONE PLUS PREDNISONE/PREDNISOLONE IN PATIENTS WITH ASYMPTOMATIC OR MILDLY SYMPTOMATIC METASTATIC CASTRATE-RESISTANT PROSTATE CANCER WITH PTEN-LOSS

    Available at 5 locations